The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma—HER2 Protein and Gene in Pancreatic Cancer

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a lethal and clinically heterogeneous disease with a limited benefit from human epidermal growth factor receptor 2 (HER2)-targeted therapy. Recently, some studies have addressed the antitumoral effect of novel anti-HER2 drugs in HER2 low-expressing tumors. However, there have been few studies on the significance of low HER2 expression and genetic heterogeneity in PDAC....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glycosylation and Glycoproteins Research
• Share to HER2/EGFR in Cancer Research
• Share to Monoclonal and Polyclonal Antibodies Research